Fate Therapeutics
Clinical trials sponsored by Fate Therapeutics, explained in plain language.
A clinical-stage biopharmaceutical company developing cellular immunotherapies for cancer and immune disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Engineered immune cells take on lupus kidney disease
Disease control Recruiting nowThis phase 2 trial is testing a new treatment called FT819 for people with lupus nephritis, a serious kidney complication of lupus. FT819 is made from donor immune cells that are engineered to target and destroy faulty B cells. The study will enroll 53 participants and aims to se…
Phase 2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a single cell therapy calm multiple autoimmune diseases?
Disease control Recruiting nowThis trial tests an investigational cell therapy called FT839 in people with active autoimmune diseases, including ANCA-associated vasculitis, inflammatory myositis, rheumatoid arthritis, lupus, and systemic sclerosis. Participants receive FT839 as two intravenous infusions, some…
Phase 1/2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New CAR T-Cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…
Phase 1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a One-Time cell infusion tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…
Phase 1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Ready-Made immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 study tests an experimental therapy called FT825, a type of immune cell that is made in a lab and can be given to any patient without needing to use their own cells. It is being tested in people with advanced solid tumors that have HER2 or other markers. The study wi…
Phase 1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC